NASDAQ:PDEX - Pro-Dex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.80 +0.55 (+3.38 %) (As of 04/26/2019 03:40 AM ET)Previous Close$16.25Today's Range$16.21 - $16.8652-Week Range$6.05 - $16.45Volume41,929 shsAverage Volume21,306 shsMarket Capitalization$69.55 millionP/E Ratio30.13Dividend YieldN/ABeta1.01 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. Receive PDEX News and Ratings via Email Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDEX Previous Symbol CUSIPN/A CIK788920 Webwww.pro-dex.com Phone949-769-3200Debt Debt-to-Equity Ratio0.25 Current Ratio7.78 Quick Ratio6.08Price-To-Earnings Trailing P/E Ratio30.13 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.47 million Price / Sales3.10 Cash Flow$0.7735 per share Price / Cash Flow21.72 Book Value$3.97 per share Price / Book4.23Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.62 million Net Margins12.64% Return on Equity18.26% Return on Assets14.30%Miscellaneous Employees80 Outstanding Shares4,140,000Market Cap$69.55 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." How were Pro-Dex's earnings last quarter? Pro-Dex Inc (NASDAQ:PDEX) released its earnings results on Thursday, August, 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.16. Pro-Dex had a net margin of 12.64% and a return on equity of 18.26%. View Pro-Dex's Earnings History. When is Pro-Dex's next earnings date? Pro-Dex is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Pro-Dex. Has Pro-Dex been receiving favorable news coverage? Media coverage about PDEX stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pro-Dex earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. Who are some of Pro-Dex's key competitors? Some companies that are related to Pro-Dex include SeaSpine (SPNE), Cytosorbents (CTSO), Nuvectra (NVTR), Apyx Medical (APYX), Liquidia Technologies (LQDA), Alphatec (ATEC), RenovaCare (RCAR), T2 Biosystems (TTOO), Sensus Healthcare (SRTS), Motus GI (MOTS), STRATA Skin Sciences (SSKN), iCAD (ICAD), Apollo Endosurgery (APEN), CAS Medical Systems (CASM) and Endologix (ELGX). What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), Magnachip Semiconductor (MX), Amtech Systems (ASYS), Alphabet (GOOG), Athersys (ATHX), Aware (AWRE), Adesto Technologies (IOTS), JA Solar (JASO), Kewaunee Scientific (KEQU) and Micron Technology (MU). Who are Pro-Dex's key executives? Pro-Dex's management team includes the folowing people: Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49) How do I buy shares of Pro-Dex? Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $16.80. How big of a company is Pro-Dex? Pro-Dex has a market capitalization of $69.55 million and generates $22.47 million in revenue each year. Pro-Dex employs 80 workers across the globe. What is Pro-Dex's official website? The official website for Pro-Dex is http://www.pro-dex.com. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected] MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 68 (Vote Outperform)Underperform Votes: 81 (Vote Underperform)Total Votes: 149MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: What are the advantages of the Stochastic Momentum Index?